Skip to content
IO Biotech logo — Break Boundaries. Ignite Change.

IO Biotech

Break Boundaries. Ignite Change.

Founded 2015 Denmark Denmark 91 employees Post-IPO Equity Total: $198.00M Biotechnology, Health Care +1

General Information

Company Name IO Biotech
Founded Year 2015
Location Denmark Denmark
Employees 91
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with IO Biotech. To contact IO Biotech, visit iobiotech.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does IO Biotech compare?

A PDF of IO Biotech and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting IO Biotech soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About IO Biotech

IO Biotech is a clinical-stage biopharmaceutical company headquartered in Copenhagen, Denmark. The company's mission revolves around pioneering a first-in-class investigational dual-action immune-modulating cancer vaccine, with the ultimate goal of serving as the backbone of combination therapy for individuals battling cancer. Their T-win® vaccine platform is specifically targeting the tumor microenvironment (TME) and aims to activate T cells against tumor cells, as well as the most crucial immune-suppressive cells within the TME.

IO Biotech has made significant progress in advancing compounds to the clinic, with their most advanced program, IO102-IO103, currently in Phase 3 development. Additionally, the company has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development, along with several compounds finalizing the preclinical phase.

Established in 2014, IO Biotech boasts an experienced management team within the immuno-oncology field and a world-class advisory board. The company recently secured a Post-IPO Equity investment on 07 August 2023 as a testament to investor confidence in their endeavors.

With a focus on the biotechnology and health care industries, IO Biotech is well-positioned to drive innovation in the fight against cancer, embodying the ethos of their slogan: "Break Boundaries. Ignite Change."

Business keywords: biopharmaceutical, clinical-stage, immune-modulating, cancer vaccine, combination therapy, TME, T-win® vaccine platform, Phase 3 development, Copenhagen, immuno-oncology, management team, advisory board

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity Undisclosed -
07 Aug 2023
Series C Undisclosed 1
HBM Healthcare Investments
07 Oct 2021
Series B €127.00M 9
Novo Holdings, HBM Healthcare Investments +7
13 Jan 2021
Debt Financing kr60.00M -
12 May 2020
Series A €11.00M -
05 Jan 2016

IO Biotech Alternatives & Competitors

View All Alternatives
IO Biotech vs

#lifeunderthesurface #BBJBestPlacesToWork2023,2022,2021 #BostonGlobeTopPlacesToWork2023,2022,2021

Post-IPO Equity
14 employees
Biotechnology, Health Care
IO Biotech vs
TME Pharma
TME Pharma Germany

Developing novel therapies for treatment of the most aggressive cancers by acting on the tumor micro...

Post-IPO Equity
12 employees
Biotechnology, Health Care
IO Biotech vs
OncoResponse
OncoResponse United States

Interrogating for Cures

10 employees
Biopharma, Biotechnology

FAQ About IO Biotech

Break Boundaries. Ignite Change.
IO Biotech was founded in 2015.
IO Biotech is headquartered in Denmark.
IO Biotech operates in Biotechnology, Health Care and Health and Wellness. Its work centres on biopharmaceutical, clinical-stage, immune-modulating and cancer vaccine.
IO Biotech has approximately 91 employees.
IO Biotech has completed 5 funding rounds, raising a total of $198.00M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to IO Biotech include Surface Oncology Inc., TME Pharma, OncoResponse, Oxford BioTherapeutics, Apollomics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
IO Biotech and Surface Oncology Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for IO Biotech, https://bouncewatch.com/company/io-biotech, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout